An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer

Therapeutic Advances in Urology

Volumn 3, Issue 3, 2011, Pages 127-140

  Boccon Gibod, Laurent ^a   Van Der Meulen, Egbert ^b   Persson, bo Eric ^b  

^a BICHAT HOSPITAL   (France)

^b Ferring Pharmaceuticals AS   (Denmark)

Author keywords

abarelix; degarelix; GnRH agonist; GnRH antagonist; prostate cancer

Indexed keywords

ABARELIX; ALKALINE PHOSPHATASE; BICALUTAMIDE; CETRORELIX; DEGARELIX; FOLLITROPIN; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; OZARELIX; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TEVERELIX;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BODY WEIGHT; CASTRATION; CHILL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FOLLOW UP; HEART SUPRAVENTRICULAR ARRHYTHMIA; HORMONE RELEASE; HOT FLUSH; HUMAN; HYPOPHYSIS GONAD SYSTEM; INJECTION SITE PAIN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OVARY INSUFFICIENCY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QT PROLONGATION; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT GAIN;

EID: 80051764006     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211414457     Document Type: Review

References (52)

1. Alibhai S.M. Duong-Hua M. Sutradhar R. Fleshner N.E. Warde P. Cheung A.M. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452–3458.
2. Amory J.K. Leonard T.W. Page S.T. O'Toole E. McKenna M.J. Bremner W.J. (2009) Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 64: 641–645.
3. Boccon-Gibod L. Klotz L. Schröder H. Andreou C. Persson B.E. Cantor P. (2008) Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients. Eur Urol (Suppl. 7): 205–205. abstract 537.
4. Broqua P. Riviere P.J. Conn P.M. Rivier J.E. Aubert M.L. Junien J.L. (2002) Pharmacological profile of a new, potent, and longacting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 301: 95–102.
5. Castellón E. Clementi M. Hitschfeld C. Sánchez C. Benítez D. Sáenz L. (2006) Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 24: 261–268.
6. Crawford E.D. Moul J.W. Shore N.D. Olesen T.K. Persson B.E. (2010a) Switching from leuprolide to degarelix vs continuous degarelix treatment – effects on long-term prostate-specific antigen control. J Urol 183(4 Suppl): e262–e262. abstract 670.
7. Crawford E.D. Moul J.W. Shore N.D. Olesen T.K. Persson B.E. (2010b) Prostate-specific antigen and serum alkaline phosphatase levels in prostate cancer patients receiving degarelix or leuprolide. J Urol 183(4 Suppl): e338–e338. abstract 866.
8. Debruyne F. Bhat G. Garnick M.B. (2006) Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2: 677–696.
9. Festuccia C. Dondi D. Piccolella M. Locatelli A. Gravina G.L. Tombolini V. (2010) Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate 70: 1340–1349.
10. Gittelman M. Pommerville P.J. Persson B.E. Jensen J.K. Olesen T.K. (2008) on behalf of the Degarelix Study Group. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 180: 1986–1992.
11. Gonzalez-Barcena D. Cardenas-Cornejo I. Vadillo-Buenfil M. Comaru-Schally A.M. Cortez-Morales A. Schally A.V. (1995) Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 45: 275–281.
12. Gonzalez-Barcena D. Vadillo-Buenfil M. Gomez-Orta F. Fuentes Garcia M. Cardenas-Cornejo I. Graef-Sanchez A. (1994) Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 24: 84–92.
13. Herbst K.L. Anawalt B.D. Amory J.K. Bremner W.J. (2002) Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab 87: 3215–3220.
14. Herbst K.L. Coviello A.D. Page S.T. Amory J.K. Anawalt B.D. Bremner W.J. (2004) Acyline, a gonadotropin releasing-hormone antagonist suppresses gonadotropins and testosterone for 15 days after a single dose. J Clin Endocrinol Metab 89: 5959–5965.
15. Huggins C. Hodges C.V. (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297.
16. Huhtaniemi I. White R. McArdle C.A. Persson B.E. (2009) Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab 20: 43–50.
17. Huirne J.A.F. Lambalk C.B. (2001) Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358: 1793–1803.
18. Johansen J.S. Brasso K. Iversen P. Teisner B. Garnero P. Price P.A. (2007) Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 13: 3244–3249.
19. Jung K. Lein M. Stephan C. Von Hösslin K. Semjonow A. Sinha P. (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111: 783–791.
20. Jungwirth A. Galvan G. Pinski J. Halmos G. Szepeshazi K. Cai R.Z. (1997) Luteinizing hormone-releasing hormone antagonist cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 32: 164–172.
21. Keating N.L. O–Malley J. Smith M.R. (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456.
22. Kirby R.S. Fitzpatrick J.M. Clarke N. (2009) Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int 104: 1580–1584.
23. Klotz L. Boccon-Gibod L. Shore N.D. Andreou C. Persson B.E. Cantor P. (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in prostate cancer patients. BJU Int 102: 1531–1538.
24. Klotz L. Smith M.R. van der Meulen E.A. Tanko L.B. (2010) Baseline cardiovascular risk factors predict cardiovascular (CV) events during androgen deprivation therapy (ADT) with degarelix. Ann Oncol 21(Suppl. 8): viii 276, abstract 883 P–viii 276, abstract 883 P.
25. Koechling W. Hjortkjaer R. Tankó L.B. (2010) Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 70: 580–587.
26. Lamharzi N. Schally A.V. Koppan M. (1998) Luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 77: 185–192.
27. Lein M. Wirth M. Miller K. Eickenberg H.U. Weissbach L. Schmidt K. (2007) Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 52: 1381–1387.
28. Levine G.N. D'Amico A.V. Berger P. Clark P.E. Eckel R.H. Keating N.L. (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121: 833–840.
29. Lorente J.A. Morote J. Raventos C. Encabo G. Valenzuela H. (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155: 1348–1351.
30. McLeod D. Zinner N. Tomera K. Gleason D. Fotheringham N. Campion M. (2001) A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58: 756–761.
31. Mongiat-Artus P. Teillac P. (2004) Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother 5: 2171–2179.
32. Oka D. Shiba M. Arai Y. Nakayama M. Takayama H. Inoue H. (2006) Skin reactions to 3-month depot type of luteinizing hormone-releasing hormone agonist therapy. Jpn Med Assoc J 49: 48–54.
33. Page S.T. Amory J.K. Anawalt B.D. Irwig M. Brockenbrough A. Matsumoto A.M. (2006) Testosterone gel combined with depomedroxyprogesterone acetate (DMPA) is an effective male hormonal contraceptive regimen but is not enhanced by the addition of the GnRH antagonist acyline. J Clin Endocrinol Metab 91: 4374–4380.
34. Persson B.E. Kold Olesen T. Jensen J.K. (2009) Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 90: 235–244.
35. Persson B.E. Olesen T.K. Jensen J. Mason M. (2010) Effects of switching from leuprolide to degarelix on long-term prostate-specific antigen (PSA) and serum alkaline phosphatase (S-ALP) control. Ann Oncol 21(Suppl. 8): viii 280–viii 280. abstract 893 P.
36. Pinski J. Yano T. Miller G. Schally A.V. (1992) Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate 20: 213–224.
37. Plekhanov A. Crawford E.D. Olesen T.K. Van Der Meulen E.A. Persson B.E. (2010) Switching from leuprolide to degarelix vs. continuous degarelix treatment – effects on long-term PSA control. Eur Urol 9(Suppl. 6): 538–538. abstract N12.
38. Princivalle M. Broqua P. White R. Meyer J. Mayer G. Elliott L. (2007) Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 320: 1113–1118.
39. Ramankulov A. Lein M. Kristiansen G. Loening S.A. Jung K. (2007) Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67: 330–340.
40. Reissmann T. Schally A.V. Bouchard P. Riethmiiller H. Engel J. (2000) The LHRH antagonist cetrorelix: a review. Hum Reprod Update 6: 322–331.
41. Robinson D. Sandblom G. Johansson R. Garmo H. Stattin P. Mommsen S. (2008) Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. J Urol 179: 117–122.
42. Schröder F.H. Tombal B. Miller K. Boccon-Gibod L. Shore N.D. Crawford E.D. (2010) Alkaline phosphatase changes in prostate cancer patients receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study (CS21). BJU Int 106: 182–187.
43. Selvaggi F. Khoe G.S.S. Van Cangh P. Jung J.-L. Schulman C.C. Vallancien G. (2001) Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomised, phase III study. Eur Urol 39(Suppl. 5): 78–78.
44. Sharma O.P. Weinbauer G.F. Behre H.M. Nieschlag E. (1992) The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate. Urol Res 20: 317–321.
45. Smith M.R. Klotz L. Persson B.E. Olesen T.K. Wilde A.A. (2010) Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel-group phase III trial in patients with prostate cancer. J Urol 184: 2313–2319.
46. Steinberg M. (2009) Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 31: 2312–2331.
47. Thompson I.M. (2001) Flare associated with LHRH-agonist therapy. Rev Urol 3(Suppl. 3): S10–S14.
48. Tombal B. Miller K. Boccon-Gibod L. Schröder F. Shore N. Crawford E.D. (2010) Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 57: 836–842.
49. Tomera K. Gleason D. Gittelman M. Moseley W. Zinner N. Murdoch M. (2001) The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165: 1585–1589.
50. Trachtenberg J. Gittleman M. Steidle C. Barzell W. Friedel W. Pessis D. (2002) A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167: 1670–1674.
51. Van Poppel H. Nilsson S. (2008) Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 71: 1001–1006.
52. Van Poppel H. Tombal B. de la Rosette J.J. Persson B.E. Jensen J.K. Olesen T.K. (2008) on behalf of the Degarelix Study Group. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase II dose-finding study in the treatment of prostate cancer. Eur Urol 54: 805–815.